Ultragenyx Pharma up after JPMorgan PT raise
** Shares of drugmaker Ultragenyx Pharmaceutical RARE.O rise 2% to $38.75 ** JPMorgan raises RARE's target price to $117 from $104 ** Believes RARE is uniquely positioned in the long term with a broad and diverse pipeline of orphan disease assets and a highly regarded management team - JPMorgan ** 19 of 20 brokerages rate the stock "buy" or higher, one "hold"; their median PT is $87, according to data compiled by LSEG ** Up to last close, stock had fallen ~10% YTD (Reporting by Juby Babu in Mexico City) ((Juby.Babu@thomsonreuters.com;))
Recent news on Ultragenyx Pharmaceutical
See all newsBrief: Ultragenyx Pharmaceutical Enters Settlement Agreement With Navinta On Dojolvi Patent Litigation - SEC Filing
Ultragenyx gains on $210 million US FDA voucher sale
Brief: Ultragenyx Pharmaceutical - Under Deal With U.S. Department Of Health Co To Pay 20% Of Prv Sale Proceeds To Nih
Brief: Ultragenyx Enters Into Agreement To Sell Rare Pediatric Disease Priority Review Voucher For $210 Million
U.S. STOCKS ON THE MOVE-CoreWeave, StubHub, Ultragenyx